1 Small-Cap Biotech Stock to Buy Right Now
Enzymes. You may not realize it, but they're pretty important to daily life. Your high-efficiency, phosphate-free laundry detergent that removes even the most stubborn stains in cold water? That's made possible through the addition of a handful of stain-fighting enzymes that work at lower temperatures. The widespread adoption of these products has saved energy from heating water and allowed brand owners to remove environment-polluting phosphates from the ingredients list.
The ability to reduce energy consumption, simplify ingredients or inputs, and reduce waste has long made enzymes important to various industrial manufacturing processes as well, including the production of stone-washed jeans, food ingredients, and pharmaceuticals. But designing enzymes that work as advertised and can be manufactured cheaply enough to enable widespread use requires a specialized technology platform.
That's where a little company called Codexis (NASDAQ: CDXS) comes in. It's not close to being the biggest enzyme company today, with a market cap of just $335 million, but a new management team has executed beautifully in recent years. As the company begins to expand its niche, you might regret not having had it in your portfolio.
Source: Fool.com